drugset / Trial / NCT04964960
Pembro+Chemo in Brain Mets
NaSingle-groupOpen-labelTreatment
Summary
The goal of this study is to evaluate whether providing Pembrolizumab prolongs survival and preserves quality of life while minimizing side effects for patients with NSCLC with untreated asymptomatic brain metastasis.
Timeline
- Start
- 2022-05-19
- Primary completion
- 2023-06-19
- Completion
- 2023-12-19
Outcome
Outcome not reported
Stopped (Enrollment): “Slow Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | — |
| Subject | Pembrolizumab | Monoclonal antibody | 400 mg | — |
| Background | Carboplatin | Small molecule | — | — |
| Background | Nab-paclitaxel | Small molecule | — | — |
| Background | Paclitaxel | Small molecule | — | — |
| Background | Pemetrexed | Small molecule | — | — |